About the bill
- Full Title
An original bill to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and medical devices, to establish user-fee programs for generic drugs and biosimilars, and for other purposes.
The bill’s title was written by its sponsor.
This is the first step in the legislative process.
Reported by Committee
A committee has issued a report to the full chamber recommending that the bill be considered further. Only about 1 in 4 bills are reported out of committee.
- Committee Assignments
The committee chair determines whether a bill will move past the committee stage.
There have been no roll call votes related to this bill.
- Subject Areas
- Related Bills
Legislative action may be ocurring on one of these bills in lieu of or in parallel to action on this bill.S. 3187 (Related)Food and Drug Administration Safety and Innovation Act
Enacted — Signed by the President
Jul 9, 2012H.R. 5651 (Related)Food and Drug Administration Reform Act of 2012
Last Action: May 30, 2012
Search for similar bills.
Links & tools
Click a format for a citation suggestion:
Civic Impulse. (2016). S. 2516 — 112th Congress: Food and Drug Administration Safety and Innovation Act. Retrieved from https://www.govtrack.us/congress/bills/112/s2516
“S. 2516 — 112th Congress: Food and Drug Administration Safety and Innovation Act.” www.GovTrack.us. 2012. May 4, 2016 <https://www.govtrack.us/congress/bills/112/s2516>
|title=S. 2516 (112th)
|accessdate=May 4, 2016
|author=112th Congress (2012)
|date=May 7, 2012
|quote=Food and Drug Administration Safety and Innovation Act